Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05995067
Other study ID # lncRNA in periodontal disease
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date February 14, 2022
Est. completion date January 30, 2024

Study information

Verified date December 2023
Source University of Baghdad
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Periodontitis is a polymicrobial, inflammatory condition affecting tooth-supporting tissues. It is characterized by a progressive loss of epithelial attachment and resorption of alveolar bone, which can lead to tooth loss. Epithelial-mesenchymal transition (EMT) has been proposed as a reversible process that shifts the cell phenotype from epithelial to mesenchymal-like and may be involved in the process of periodontal inflammation either completely or partially. Long non-coding RNAs (lncRNAs) are a large class of regulatory transcripts longer than 200 nucleotides lacking evident protein-coding potential. Studies have shown that lncRNA dysregulation plays key roles in human diseases, including cancer, by modulating the epithelial-mesenchymal transition (EMT). The involvement of lncRNAs markers in the pathogenesis of periodontal disease induced EMT has not been studied thoroughly and have created a gap in the knowledge.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 48
Est. completion date January 30, 2024
Est. primary completion date January 30, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Patients with no history of systemic disease e.g., diabetes. - Both males and females will be included in the study. - Control group: patients fit the case definition of gingival health2, and confirmed by Histopathological inflammatory cell infiltration analysis. - Periodontitis group: patients fit the case definition of periodontal disease referred for periodontal flap surgery (modified Widman's flap). - Patients radiographically confirmed with infrabony pocket eligible for periodontal flap surgery. Exclusion Criteria: - Patients not willing to participate or consent. - Patient taking medications that affect or modify immunity (e.g., corticosteroid), for the last 3 months. - Patient taking NSAIDs for the last 3 months. - Active smoker.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
periodontitis challenge
control will be compared to diseased group suffering from periodontal disease.

Locations

Country Name City State
Iraq saif mohammed T AL Mufti Baghdad

Sponsors (1)

Lead Sponsor Collaborator
Ali A Abdulkareem

Country where clinical trial is conducted

Iraq, 

Outcome

Type Measure Description Time frame Safety issue
Primary determining the relative expression of lncRNAs (NEAT1 and MALAT1) in healthy and diseased periodontal tissue. reverse transcription real time polymerase chain reaction one year
Secondary determine the expression of EMT-related genes (E-cadherin, Vimentin, ß-catenin, and Snail1), in healthy and diseased tissues, and their correlation with lncRNAs and clinical parameters. reverse transcription real time polymerase chain reaction one year
See also
  Status Clinical Trial Phase
Recruiting NCT03509779 - Pronostic and Predictive Value of EMT in Localized Lung Cancer